The rise of Viagra and its impact on the drug landscape presents a complex question for shareholders. While the early sales figures were astounding, the exclusivity has expired, leading to a deluge of generic alternatives that are eroding earnings. In addition, the market is facing challenges related to demographic trends and shifting healthcare re